Device Treatment Selection. Studies reasonably anticipated to show the role of Galectin-3 in identifying responders for CRT or other device treatments in classes of patients that are not currently considered for these treatments.
Appears in 5 contracts
Samples: Galectin 3 License and Distribution Agreement (BG Medicine, Inc.), Galectin 3 License and Distribution Agreement (BG Medicine, Inc.), Galectin 3 License and Distribution Agreement (BG Medicine, Inc.)